Effect of CYP3A5, CYP3A4, and ABCB1 genotypes as determinants of tacrolimus dose and clinical outcomes after heart transplantation

Transplantation Proceedings

Volumn 44, Issue 9, 2012, Pages 2635-2638

  Diaz Molina B ^a   Tavira, B ^a   Lambert, J L ^a   Bernardo, M J ^a   Alvarez V ^a   Coto, E ^a  

^a HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DACLIZUMAB; METHYLPREDNISOLONE; MULTIDRUG RESISTANCE PROTEIN 1; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ADULT; CARDIAC GRAFT REJECTION; CONFERENCE PAPER; DIABETES MELLITUS; DRUG BLOOD LEVEL; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; GRAFT RECIPIENT; HEART TRANSPLANTATION; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEW ONSET DIABETES AFTER TRANSPLANTATION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; ANALYSIS OF VARIANCE; CYTOCHROME P-450 CYP3A; DIABETES MELLITUS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; HOMOZYGOTE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LINEAR MODELS; LOGISTIC MODELS; MALE; MIDDLE AGED; P-GLYCOPROTEIN; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK ASSESSMENT; RISK FACTORS; TACROLIMUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84869063748     PISSN: 00411345     EISSN: 18732623     Source Type: Journal    
DOI: 10.1016/j.transproceed.2012.09.062     Document Type: Conference Paper

References (17)

1. R. Venkataramanan, A. Swaminathan, T. Prasad Clinical pharmacokinetics of tacrolimus Clin Pharmacokinet 29 1995 404
2. R.H. Hu, P.H. Lee, M.K. Tsai Clinical influencing factors for daily dose, trough level, and relative clearance of tacrolimus in renal transplant recipients Transplant Proc 32 2000 1689
3. H. Tada, N. Tsuchiya, S. Satoh Impact of CYP3A5 and MDR1(ABCB1) C3435T polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients Transplant Proc 37 2005 1730
4. E. Thervet, D. Anglicheau, B. King Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients Transplantation 76 2003 1233
5. Y. Dai, M.F. Hebert, N. Isoherranen Effect of CYP3A5 polymorphism on tacrolimus metabolic clearance in vitro Drug Metab Dispos 34 2006 836
6. J.S. Chen, L.S. Li, D.R. Cheng Effect of CYP3A5 genotype on renal allograft recipients treated with tacrolimus Transplant Proc 41 2009 1557
7. I.A. Macphee, S. Fredericks, T. Tai Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement Transplantation 74 2002 1486
8. P. Kuehl, J. Zhang, Y. Lin Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression Nat Genet 27 2001 383
9. D.R. Kuypers, M. Naesens, H. de Jonge Tacrolimus dose requirements and CYP3A5 genotype and the development of calcineurin inhibitor-associated nephrotoxicity in renal allograft recipients Ther Drug Monit 32 2010 394
10. K.R. Jun, W. Lee, M.S. Jang Tacrolimus concentrations in relation to CYP3A and ABCB1 polymorphisms among solid organ transplant recipients in Korea Transplantation 87 2009 1225
11. J.H. Cho, Y.D. Yoon, J.Y. Park Impact of cytochrome P450 3A and ATP-binding cassette subfamily B member 1 polymorphisms on tacrolimus dose-adjusted trough concentrations among Korean renal transplant recipient Transplant Proc 44 2012 109
12. B. Tavira, E.C. Garcia, C. Diaz-Corte Pharmacogenetics of tacrolimus after renal transplantation: analysis of polymorphisms in genes encoding 16 drug metabolizing enzymes Clin Chem Lab Med 49 2011 825
13. J.M. Armitage, R.L. Kormos, J. Fung The clinical trial of FK 506 as primary and rescue immunosuppression in adult cardiac transplantation Transplant Proc 23 1991 3054
14. E. Thervet, M.A. Loriot, S. Barbier Optimization of initial tacrolimus dose using pharmacogenetic testing Clin Pharmacol Ther 87 2010 721
15. B. Tavira, E. Coto, C. Diaz-Corte KCNQ1 gene variants and risk of new-onset diabetes in tacrolimus-treated renal-transplanted patients Clin Transplant 25 2011 E284
16. M. Naesens, E. Lerut, H. de Jonge Donor age and renal P-glycoprotein expression associate with chronic histological damage in renal allografts J Am Soc Nephrol 20 2009 2468
17. S. de Denus, M. Zakrzewski, A. Barhdadi Association between renal function and CYP3A5 genotype in heart transplant recipients treated with calcineurin inhibitors J Heart Lung Transplant 30 2011 326